NCT00086515View on ClinicalTrials.gov

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

701

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

July 20, 2005

Study Completion Date

February 2, 2007

Conditions

Diabetes Mellitus, Type II

Interventions

DRUG

Sitagliptin (MK0431)

Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104

DRUG

Placebo/Glipizide 5 mg

Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)

DRUG

Metformin

Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)

DRUG

Pioglitazone

Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00086515 - Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) | Biotech Hunter | Biotech Hunter